Specialty Pharmacy

An ACR session focused on the Sunshine Act and health care transparency.

Baricitinib is a once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of autoimmune and inflammatory diseases.

Two pilot studies are transplanting infected kidneys into patients and then treating them with curative hepatitis C medications.

Sarilumab shows promise on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate.

Patients with rheumatoid arthritis who demonstrate a less-than-adequate response to a tumor necrosis factor inhibitor can be treated with another disease-modifying antirheumatic drug.

Regulatory perspectives presented at ACR on biosimilars entering the market convey the importance of crafting antibodies to our own purposes.

Low health literacy, financial instability, and lack of social support promote poor adherence.

Top news of the day from across the health care landscape.

Zepatier shows promise across genotypes 1 and 4, even among patients administered opioid agonist therapy.

Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, senior director of Specialty Clinical Services at Managed Health Care Associates, discusses how specialty stakeholders will need to alter current patient management programs as new drugs transform the treatment of diseases into more manageable conditions.

New guidelines for rheumatoid arthritis treatment discussed at ACR conference.

Broadly neutralizing antibody delays viral rebound and opens doors for future HIV vaccines.

ACR session reinforces the need for new research about how the genome, epigenome, and other factors play a role in rheumatoid arthritis.

CD98 molecule could be a potential therapeutic target in AML.

Comparing healthy and cancerous cells from the same individual could allow for a better understanding of translocations involved.

There is building consensus that multiple sclerosis and rheumatoid arthritis display similar autoimmune genetic pathways.

Vemlidy treats patients with chronic hepatitis B infection with compensated liver disease.

Top news of the day from across the health care landscape.

National Association of Specialty Pharmacy emphasizes work with manufacturers, prescribers and payers to ensure the availability of specialty medications and services that ensure optimal patient outcomes.

Specialty pharmacies must be prepared to innovate as biosimilars hit the US market.

Opdivo is approved for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma.

Gilenya may cause an increase in CD56+-expressing T cells, which can cause MS relapse.

A newly identified metabolic fingerprint of colorectal cancer may serve as a future diagnostic tool in early detection.

John Campo, vice president of Specialty Pharmacy Trade Relations and Contracting at Managed Health Care Associates, discusses optimal use of data analytics in specialty pharmacy.

Top news of the day from across the health care landscape.

Clinicians who marry technical skills with humanities can see their patients and themselves in the larger context of family, society, history, politics, and economics.

Using data and bioinformatics could hold the key to numerous treatment options.

Anti-tumor necrotic factor drugs could help delay hip deterioration in patients with ankylosing spondylitis.

Research evaluates sofosbuvir use in hepatitis C patients with a mental health disease.

Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke.